Disease/Condition
320 Clinical Trials
10+ Countries
Non-small cell lung cancer Clinical Trials Database - Free Access to 320 Studies
Access comprehensive clinical trial information for Non-small cell lung cancer through Pure Global AI's free database. This collection includes 320 clinical trials across multiple phases including N/A, Phase 2, Not Applicable. Currently, 57 trials are actively recruiting participants.
Research for Non-small cell lung cancer is being conducted in Japan, China, South Korea and 7+ other countries. Leading sponsors include West Japan Oncology Group and Niigata Lung Cancer Treatment Group. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Free Database
Powered by Pure Global AI
840K+ Global Trials
Updated Daily
By Phase
N/A
128Phase 2
96Not Applicable
54Phase 1
13Phase 3
12By Status
Completed
129Recruiting
57Terminated
37Recruitment Com...
29Not yet recruit...
25Top Countries
Japan234
China33
South Korea5
United Kingdom4
Australia3
Top Sponsors
West Japan Oncolog...14
Niigata Lung Cance...8
Thoracic Oncology ...7
North East Japan S...5
National Cancer Ce...4
Recent Trials
Latest clinical trials for Non-small cell lung cancer
UMIN000052408
Recruiting
A prospective observational study to assess the utility of comprehensive genomic profiling in patients with non-small cell lung cancer without driver genetic alterations
Hamamatsu University School of...Japan
UMIN000052404
Recruitment ...
Changes in lymphoid tissue proliferation with PD-1 inhibitor therapy for lung cancer using FLT-PET/MRI; a retrospective study
University of FukuiJapan
UMIN000051670
Not Applicable
Not yet recr...
A multicenter retrospective observational study to evaluate the efficacy and safety of durvalumab following concurrent chemoradiotherapy for stage III non-small cell lung cancer harboring EGFR mutation (NEJ063 study)
Tohoku University HospitalJapan
UMIN000050878
Enrolling by...
Prospective observational study to evaluate the efficacy of anamorelin on the course of first line chemotherapy in patients with previously-untreated advanced non-small cell lung cancer and cachexia (NEJ050B)
North East Japan Study Group (...Japan
UMIN000050723
Not yet recr...
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.
Kobe UniversityJapan
UMIN000050729
Recruiting
Whole genome analysis in patients with resected non-small cell lung cancer (WJOG16622L)
West Japan Oncology GroupJapan
UMIN000050478
Recruiting
A prospEctive observatioNal study evaluating profiling of T cell binding to anti-PD-1 antibody using peripHeral blood as signAture for tumor respoNse during ramuCirumab and docEtaxel afteR anti-PD-1 antibody
Graduate School of Medicine, O...Japan
UMIN000049936
Recruiting
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Graduate School of Medicine, O...Japan
UMIN000049680
Completed
Future prospects for therapeutic strategies for brain metastases and acquired resistance in the treatment of ALK positive advanced non small cell lung cancer. A comprehensive literature review with network meta-analysis.
Showa University school of med...Japan
UMIN000049225
Enrolling by...
Rechallenge of afatinib for EGFR mutated non-small cell lung cancer previously treated with osimertinib
Shinshu University School of M...Japan
UMIN000049194
Recruitment ...
Multicenter retrospective study evaluating the efficacy and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer.
North East Japan Study GroupJapan
UMIN000048902
Not Applicable
Recruitment ...
Ancillary study for the "phase III Study of adjuvant chemotherapy for the patients resected pathological stage I (T1>2cm) non-small cell lung cancer": Evaluation of long-term prognosis after resection for early-stage non-small cell lung cancer (JCOG0707A1)
Japan Clinical Oncology Group ...Japan
UMIN000048869
Not yet recr...
Exploratory integrated analysis to build a pathologic finding, recurrence, survival predicting algorithm using artificial intelligence from clinical factors and image finding on thin-section computed tomography in patients with clinical stage IA non-small cell lung cancer
JCOGJapan
ChiCTR2200059753
Not Applicable
Completed
Untitled Trial
Xiangya Hospital of Central So...China
KCT0007091
Phase 2
Recruiting
Untitled Trial
Yonsei University Health Syste...South Korea
ChiCTR2200057534
Not Applicable
Not yet recr...
Untitled Trial
chinese peoples liberation arm...China
UMIN000047162
Not yet recr...
Investigation of biomarkers to predict immune-related adverse events in patients with non-small cell lung cancer
Kobe UniversityJapan
ISRCTN70247820
Phase 3
Reduced frequency pembrolizumab immunotherapy: can the frequency of pembrolizumab treatment for non-small cell lung cancer be reduced without reducing its effectiveness?
Imperial College LondonUnited Kingdom
UMIN000046913
Not Applicable
Completed
Relationship between local control rate and overall survival rate in stereotactic body radiotherapy for early-stage lung cancer: systematic review
Ofuna Chuo HospitalJapan
KCT0006973
Phase 2
Not yet recr...
Untitled Trial
Yonsei University Health Syste...South Korea
About Non-small cell lung cancer Research
Pure Global AI provides free access to 320 clinical trials studying Non-small cell lung cancer, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include West Japan Oncology Group, Niigata Lung Cancer Treatment Group, Thoracic Oncology Research Group, among others.
Quick Facts
Total Trials320
Countries10+
Sponsors10+
Recruiting57